RxDoctor Payments Data

Mili Shah, MD

Internal Medicine · Syracuse, NYNPI 1780038513

Payments from drug & device makers

$2,033in general payments, 2019–2025

Across 91 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$692
  • Novo Nordisk$443
  • AstraZeneca$110
  • E.r. Squibb & Sons, L.L.C.$109
  • Pfizer$81
  • Shionogi Inc$80
  • plus $518 from 11 others

What the payments were for

  • Food & beverage$2,033100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,033 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$78,739
Medicare patients
175
Services billed
1,639

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$28,777
EliquisApixaban23$28,435
MounjaroTirzepatide20$27,016
JardianceEmpagliflozin12$19,249
FarxigaDapagliflozin Propanediol11$12,345
LinzessLinaclotide13$8,742
Levothyroxine Sodium80$2,646
Atorvastatin Calcium146$1,783
SynthroidLevothyroxine Sodium20$1,687
Rosuvastatin Calcium106$1,579
Losartan Potassium93$949
Bupropion XlBupropion Hcl18$820
Gabapentin37$789
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide15$773
Montelukast Sodium48$751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$443$28,77719 claims
PfizerEliquis$81$28,43523 claims
Lilly USA, LLCMounjaro$37$27,01620 claims
Boehringer IngelheimJardiance$75$19,24912 claims
AstraZenecaFarxiga$110$12,34511 claims
AbbVieLinzess, Synthroid$20$10,42933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →